IMPORTANCE A significant number of patients receive bare-metal stents (BMSs) instead of drug-eluting stents (DESs) to shorten the duration of dual antiplatelet therapy (DAPT). Emerging evidence suggests that new-generation DESs, particularly those optimized for biocompatibility, may be more efficacious and safer than BMSs, even with a single month of DAPT after stent implantation.
C urrent evidence supports the superiority of drugeluting stents (DESs) over bare-metal stents (BMSs) for coronary stenosis in most clinical settings. 1 However, both stent types induce platelet adhesion and activation, leading to stent thrombosis; therefore, dual antiplatelet therapy (DAPT) is the cornerstone treatment for patients with coronary artery stents. 2 Because the risk of stent thrombosis is greatest during the first 30 days after BMS implantation, current guidelines recommend DAPT for at least 1 month in patients with stable ischemic heart disease. 2 In the past, safety concerns led to the recommendation for 12 months of DAPT after implantation of a first-generation DES. 3, 4 Although stent thrombosis risk has significantly decreased with newgeneration DESs, current guidelines continue to recommend at least 6 months of DAPT after DES implantation. 1, 2, 5 Estimates show that at least 15% of these patients are not candidates for prolonged DAPT, either because of perceived bleeding risk or because compliance with DAPT is doubted for medical, social, or economic reasons. [6] [7] [8] [9] [10] Therefore, default management, supported by current guidelines, favors the use of a BMS followed by 1 month of DAPT. 2, 3 Emerging evidence suggests that new-generation DESs, particularly those optimized for biocompatibility, might not only be safe but also more efficacious compared with BMSs, even when followed by a single month of DAPT. 7, 9, [11] [12] [13] To confirm this, a meta-analysis of RCTs was performed, comparing the efficacy and safety of DESs and BMSs when each are followed by a single month of DAPT.
Methods

Data Sources and Searches
This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for systematic reviews and meta-analyses. 14 Computerized literature searches of the PubMed and Cochrane databases from their respective inceptions through March 2018 were conducted without language restrictions to locate relevant studies, and relevant articles were cross-referenced. Searches were performed using various combinations of the terms drug-eluting stents, bare-metal stents, percutaneous coronary intervention, antiplatelet therapy, and clinical trial.
Study Selection
Randomized clinical trials (RCTs) were included if they enrolled patients undergoing percutaneous coronary intervention and randomly assigned each patient to treatment with either a DES or BMS. One additional inclusion criterion was use of only 1 month of DAPT after stent implantation. Duplicate reports were excluded, as were those that compared DAPT use that was not of the same length for both the groups receiving DESs or BMSs; where necessary, subgroup data were extracted to meet this criterion.
Data Extraction and Study Quality
Two investigators (R.S. and S.B.L.) independently extracted data pertaining to study characteristics, design, and outcomes. The efficacy end points were major adverse cardiac events (MACEs), myocardial infarction (MI), target vessel revascularization (TVR), ischemia-driven target lesion revascularization (TLR), cardiac mortality, and all-cause mortality at 1 year. Study definitions were used for the MACEs outcome. The safety outcomes were stent thrombosis (definite or probable, as defined by the Academic Research Consortium) and bleeding complications (according to the Bleeding Academic Research Consortium [BARC], classifications 2 through 5). 15 In these trials, independent clinical-events committees, whose members were unaware of study group assignments, adjudicated the end points. The potential risk of bias in RCTs was appraised using the Cochrane Collaboration guidelines. 16 
Data Synthesis and Analysis
A standard pairwise meta-analysis was performed according to the Comprehensive Meta-Analysis system, version 3 (Biostat Inc). Pooled odds ratios (ORs) were calculated using random-effects models, because it is the most conservative methodology to account for between-trial heterogeneity. However, in random-effects models, power can be low even when tens of thousands of patients are included if the number of studies is small and between-study variance is nontrivial. 17 Therefore, an additional sensitivity analysis was performed using a fixed-effects mode. 17 Heterogeneity across trials was evaluated using the Cochran Q test and the Higgins I 2 test. 18 Publication bias was not assessed because the number of included trials was inadequate (<10) to properly assess a funnel plot or to use more advanced regression-based assessments. 19 
Results
Study Selection and Patient Population
Three RCTs that included 3943 patients satisfied the inclusion criteria. 7, 11, 13 The search flow diagram is shown in eFigure 1 in the Supplement. The bias assessment for each RCT is shown in eFigure 2 in the Supplement. These studies were highquality trials based on Cochrane Collaboration guidelines (eFigure 2 in the Supplement). The eTable in the Supplement shows the inclusion and exclusion criteria for each trial.
Key Points
Question What is the optimal stent strategy for coronary intervention in patients with high risk for bleeding in whom a short course of dual antiplatelet therapy is preferred?
Findings In this meta-analysis of randomized clinical trials involving 3943 patients, we found that coronary intervention with drug-eluting stents decreased the risk for myocardial infarction, target vessel revascularization, ischemia-driven target lesion revascularization, and stent thrombosis compared with bare-metal stents used with 1 month of dual antiplatelet therapy.
Meaning
In patients with high bleeding risk, coronary interventions with drug-eluting stents optimized for biocompatibility appear preferable over those with bare-metal stents.
Among the identified trials, we extracted subgroup data from 2 so that inclusion criteria could be met. Specifically, the Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) trial prespecified DAPT use based on inclusion criteria 11, 12 ; therefore, we used data from the subgroup prespecified to receive the 30-day regimen. 11 In the Syn- ; a composite of all-cause death, MI, or TVR in the ZEUS trial 11 ; and a composite of all-cause mortality, MI, TLR, or stroke in the SENIOR trial.
13
Study Findings
The 
Clinical Outcomes
Coronary intervention with DES (optimized for biocompatibility), compared with BMSs, reduced MACE rates at 1 year (OR, 0.68 [95% CI, 0.57-0.82]; P < .001; Figure 1 ). No between-trial heterogeneity was found (Q = 0.35; P =. 8 3; (Figure 3 ). In addition, moderate betweentrial heterogeneity (Q = 4.09; P = .12; I 2 = 51.1%) was found for the risk of stent thrombosis. Finally, no significant differences were found between the 2 stent types for the risk of bleeding on Bleeding Academic Research Consortium scale levels 2 through 5 (OR, 0.84 [95% CI, 0.66-1.08]; P = .20; Figure 3 ). No between-trial heterogeneity was found (Q = 2.33; P = .31; I 2 = 14.1%) for the bleeding complication. Sensitivity analysis using fixedeffects models did not change the summary results (eFigure 4intheSupplement). 
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Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents and 1 Month of Dual Antiplatelet Therapy
Discussion
In this study of 3943 patients enrolled in 3 RCTs, we compared the efficacy and safety of DESs (optimized for biocompatibility) and BMSs with a single month of DAPT. No significant differences in the rates of cardiac mortality, all-cause mortality, or bleeding consistent with Bleeding Academic Research Consortium scale levels 2 through 5 were found between the 2 stent types. The rate of stent thrombosis was numerically lower with DES, but the difference was not statistically significant in the random-effects model. However, DES use significantly decreased risks of MACEs, MI, TVR, and TLR at 1 year compared with BMS use. These results suggest that guidelines recommendations regarding the routine use of BMSs for patients with high bleeding risk or those who are uncertain candidates for DAPT (with the sole goal of shortening DAPT duration) are no longer warranted with the availability of current-generation DES, particularly those optimized for biocompatibility. Several RCTs have shown that DESs, compared with BMSs, markedly decrease the incidence of restenosis and TVR. Thus, they have become the mainstay for native vessel percutaneous coronary intervention. 1 However, because very late stent thrombosis with firstgeneration DES has a relatively high incidence, a prolonged course of DAPT was mandated after DES implantation. 4 It is estimated that at least 15% of patients might not be candidates for prolonged DAPT because of high bleeding risk or were uncertain candidates owing to poor compliance. [6] [7] [8] The use of a DES is an American Heart Association/American College of Cardiology class III (harmful) recommendation for those pa- b Data for overall SENIOR trial population. 13 Study investigators did not report data for individual subgroups.
c Although all commercially available thin-strut BMS (strut thickness <100 μm) were allowed to be used in the study, these 5 were the most commonly used devices in this stent group.
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tients who are not likely to be able to tolerate and comply with prolonged DAPT or if this cannot be determined before stent implantation. 3 Therefore, their default management, supported by current guidelines, favors the use of a BMS followed by 1 month of DAPT. 2, 3 A recent study using the CathPCI Registry showed that 1 in 5 contemporary percutaneous coronary intervention procedures in patients aged 65 years or older continue to use BMS implantation. 10 Recent RCTs and meta-analyses have suggested that newgeneration DESs have better safety and efficacy profiles than first-generation DESs. 1 In addition, recent network metaanalyses suggest that new-generation DESs might be associated with lower rates of stent thrombosis compared with BMSs. 1, 5 A possible factor confounding the results of those network meta-analyses is their varying durations of DAPT between DESs and BMSs. 1 However, additional sensitivity analyses suggest a significant difference in stent thrombosis rates between DESs and BMSs as few as 30 days after implantation, a period during which all patients are treated with DAPT irrespective of stent type. 5 Therefore, based on these safety data, new RCTs have been conducted in patients with high bleeding risk to compare new-generation DESs with BMSs followed by a single month of DAPT. 7, [11] [12] [13] Consistent with these trials, our meta-analysis suggests that DESs are not only safe but more efficacious compared with BMSs with a single month of DAPT. It also shows that DESs not only improved soft outcomes (ie, revascularization) compared with BMSs, but also hard outcomes, such as MI, with this shorter duration of DAPT. The risk of stent thrombosis was lower with DESs in this meta-analysis, but this did not reach statistical significance in random-effects models, most likely because of a type II error (lack of power). In random-effects models, power can be low even if tens of thousands of patients are included when the number of studies is small. 17 We also identified moderate heterogeneity for the outcome of stent thrombosis; this is probably driven by the ZEUS trial, 11 given the rate of stent thrombosis was higher in this trial compared with the others. The higher stent thrombosis rate in the ZEUS trial 11 
OR (95% CI)
Study Name OR (95% CI) LEADERS FREE, 7 that nonemergent, uncomplicated TLR after percutaneous coronary intervention is an independent predictor of longterm mortality, driven partly by higher rates of MI. 22 Therefore, in our meta-analysis, significantly lower MI rates with DESs are likely driven by lower stent thrombus-associated and restenosis-associated MI. Prevailing wisdom also suggests that in patients with high bleeding risk, DES implantation followed by a single month of DAPT will also be safer than the same with BMS implantation because the latter will be associated with higher rates of TVR requiring repeated DAPT. In the ZEUS trial, despite comparable protocolmandated DAPT durations in both stent groups, cumulative treatment duration with DAPT was significantly longer with BMSs. 11, 12 This leads to a nearly 2-fold rate of cumulative bleeding end points in the BMS group compared with the DES group.
11,12
Consistent with our findings, several observational studies have challenged the current contemporary practice of the preference for BMS use in patients who plan to undergo noncardiac surgery. [23] [24] [25] Current evidence suggests that contemporary DES use is associated with better outcomes than BMS use in patients undergoing noncardiac surgery, even with early (1-6 months) DAPT discontinuation after noncardiac surgical procedures. [23] [24] [25] Similarly, several recent RCTs, metaanalyses, and observational studies have consistently shown that new-generation DESs are associated with lower risks for stent thrombosis and revascularization compared with BMSs across a broad spectrum of patient populations. 1, 5, [26] [27] [28] [29] [30] The lower risk of early stent thrombosis with DESs seems to be the result of reduced acute thrombogenicity from polymer coatings. [31] [32] [33] It has been shown that well-designed polymer coatings serve as corrosive barriers and provide thromboresistance through modifications of certain properties such as surface potential, wettability, and roughness. 32, 33 On the other hand, the dominant mechanism for the lower rate of revascularization with DESs results from inhibition of in-stent neointimal hyperplasia from the antiproliferative and antiinflammatory medication eluted by DESs. 31, 33 However, the lower risk of restenosis with first-generation DESs has been associated with increases in late ischemic events attribute to delayed endothelial healing, polymer hypersensitivity reactions, positive remodeling with late acquired malposition, and neoatherosclerosis. 31, 33 Those shortcomings have been addressed with the current generation of DESs through the use of biocompatible polymers, biodegradable polymers, or removal of the polymer, along with improved platform design, 
OR (95% CI)
Study Name OR (95% CI) .39 LEADERS FREE, 7 2015 0.881 (0.662-1.174)
.56 ZEUS, 11 2016 0.895 (0.621-1.292)
.47 SENIOR, 13 
Study Name OR (95% CI)
.20 LEADERS FREE, 7 2015 0.778 (0.532-1.138)
.72 ZEUS, 11 The odds ratio estimate of each study is indicated by a square whose size represents the weight that the corresponding study had in the meta-analysis. The exact mechanisms underlying the development of neoatherosclerosis remains unknown; however, the presence of an incompetent endothelium (with an impaired endothelial cell barrier) is more likely to lead to neoatherosclerosis after stenting with a DES. 33,34 Therefore, long-term follow-up of patients in
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the reported trials will demonstrate whether benefits persist for several years.
Limitations
This meta-analysis has several limitations. First, some data were based on subgroups, and the findings should be interpreted cautiously; however, all subgroup analyses were prespecified in the trial protocols. Second, we did not have access to individual-participant data; therefore, the data we analyzed were combined from various studies, each with its own protocol, inclusion and exclusion criteria, and definitions. Specifically, the criteria defining high bleeding risk varied across trials; however, most patients in these trials were enrolled based on older age as the high bleeding risk criteria. In addition, most of those included in this analysis were patients with stable coronary artery disease. Therefore, our findings might not be generalizable to younger patients with acute coronary syndrome. Third, in the ZEUS trial, 11 the Endeavor ZES stent was used, but it is no longer commercially available. Furthermore, the BioFreedom stent was used in the LEADERS FREE trial, 7 and it is based on a poorer stent platform in that the struts are thicker in comparison with most contemporary DES models. In addition, most patients in this meta-analysis received polymer-free or bioresorbable polymer DESs. Even so, our meta-analysis did not include all contemporary bioabsorbable polymer DESs available worldwide.
35 Thus, our findings should not be generalized across all newgeneration DES platforms (either with durable polymer or bioresorbable polymer platforms). Despite these limitations, this is the first meta-analysis addressing this topic, and it will assist physicians in deciding the best stent strategy for patients who have high bleeding risk or are uncertain candidates for prolonged DAPT. Within the interventional cardiology community, there has been a growing refrain over the past few years: "There is no current role for a bare-metal stent (BMS)." This sentiment largely speaks to the rapid advancements of drug-eluting stent (DES) technology over the last decade and a half. There is no doubt that the current generation of DES devices are more efficacious and safer than predecessor devices, having been optimized for biocompatibility with thinner and thinner struts to reduce turbulent flow and specially designed polymers that serve to regulate the delivery of anti-restenotic drug therapy and can be thromboresistant, promote endothelialization, and, in some cases, resorb entirely over a relatively short time frame. Whether these modifications to DES design have eliminated the need for longer durations of dual antiplatelet therapy (DAPT) to prevent stent thrombosis in the early months after stent implantation is an area of debate, however. One DES approved for use outside the United States has even eliminated the use of a polymer altogether and has been demonstrated to be more efficacious and safer with 1 month of DAPT than a similar comparator BMS. 1 In this issue of JAMA Cardiology, Shah et al 2 provide a metaanalysis of the extremely limited randomized clinical trial data examining a single month of DAPT after DES implantation, compared with BMS use. 2 The accompanying eloquent and insightful editorial by Kereiakes 3 summarizes the limitations of this analysis but also contextualizes the findings within the greater amalgam of data on current-generation DES efficacy and safety. While both articles are supportive of the evolving dominance of DES use over BMS use, even with shorter durations of DAPT, they also highlight the need for additional (and currently ongoing) prospective and randomized data clearly establishing the safety of shorter durations of DAPT with current-generation DES devices. Notably, 2 of the DES devices examined within the metaanalysis (Endeavor and BioFreedom) are not currently available in the United States. Additionally, there are still very rarely occurring clinical scenarios (eg, active severe bleeding, need for expedited surgical procedures, or incontrovertible evidence of an inability to take medications for a month) that may require DAPT durations even shorter than 1 month. Whether percutaneous coronary intervention is indicated at all in these scenarios is always a legitimate question, but for the very short term (until newer DES data and/or device approvals emerge), I personally would grant a respite to the extremely rare case of BMS implantation that might occur in these extreme scenarios.
